GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » ROE % Adjusted to Book Value

Lantern Pharma (Lantern Pharma) ROE % Adjusted to Book Value : -21.42% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma ROE % Adjusted to Book Value?

Lantern Pharma's ROE % for the quarter that ended in Mar. 2024 was -56.77%. Lantern Pharma's PB Ratio for the quarter that ended in Mar. 2024 was 2.65. Lantern Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -21.42%.


Lantern Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Lantern Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantern Pharma ROE % Adjusted to Book Value Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -9.41 -21.85 -19.10 -29.40

Lantern Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.49 -29.65 -32.93 -34.64 -21.42

Competitive Comparison of Lantern Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Lantern Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantern Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's ROE % Adjusted to Book Value falls into.



Lantern Pharma ROE % Adjusted to Book Value Calculation

Lantern Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-32.93% / 1.12
=-29.40%

Lantern Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-56.77% / 2.65
=-21.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantern Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantern Pharma (Lantern Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini director 1223 FOXGLOVE LANE, WEST CHESTER PA 19380

Lantern Pharma (Lantern Pharma) Headlines

From GuruFocus